Sky Blue 11 Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Sky Blue 11 zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Semiconductor Gewinnwachstum	31.0%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Sky Blue 11 Company Limited's (HKG:1010) 32% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Aug 07

Balk 1798 Group Limited (HKG:1010) Soars 29% But It's A Story Of Risk Vs Reward

Mar 14

It's Down 26% But Balk 1798 Group Limited (HKG:1010) Could Be Riskier Than It Looks

Jan 23

Not Many Are Piling Into Balk 1798 Group Limited (HKG:1010) Stock Yet As It Plummets 26%

Jan 22

If You Had Bought PacRay International Holdings' (HKG:1010) Shares Three Years Ago You Would Be Down 34%

Jan 13

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Sky Blue 11 jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

SEHK:1010 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (HKD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2024	28	-70	-72	-72	N/A
3/31/2024	71	-58	-53	-53	N/A
12/31/2023	114	-46	-33	-33	N/A
9/30/2023	177	-17	-6	-6	N/A
6/30/2023	239	12	21	21	N/A
3/31/2023	210	5	20	20	N/A
12/31/2022	181	-2	20	20	N/A
9/30/2022	138	-30	-56	-55	N/A
6/30/2022	95	-57	-132	-130	N/A
3/31/2022	100	-55	-133	-131	N/A
12/31/2021	106	-53	-134	-132	N/A
9/30/2021	109	-34	-59	-57	N/A
6/30/2021	112	-15	17	17	N/A
3/31/2021	102	-10	20	20	N/A
12/31/2020	93	-5	23	23	N/A
9/30/2020	91	-10	19	17	N/A
6/30/2020	89	-14	14	11	N/A
3/31/2020	82	-17	3	2	N/A
12/31/2019	74	-21	-9	-8	N/A
9/30/2019	60	-32	-20	-18	N/A
6/30/2019	45	-43	-31	-29	N/A
3/31/2019	53	-42	-33	-30	N/A
12/31/2018	61	-40	-35	-32	N/A
9/30/2018	61	-24	-42	-38	N/A
6/30/2018	61	-7	-49	-44	N/A
3/31/2018	49	-5	N/A	-31	N/A
12/31/2017	37	-3	N/A	-19	N/A
9/30/2017	29	0	N/A	-8	N/A
6/30/2017	21	3	N/A	3	N/A
3/31/2017	19	-1	N/A	-3	N/A
12/31/2016	17	-5	N/A	-9	N/A
9/30/2016	16	-14	N/A	-9	N/A
6/30/2016	14	-23	N/A	-9	N/A
3/31/2016	14	-24	N/A	-12	N/A
12/31/2015	14	-25	N/A	-14	N/A
9/30/2015	14	-22	N/A	-13	N/A
6/30/2015	14	-19	N/A	-12	N/A
3/31/2015	14	-1	N/A	-9	N/A
12/31/2014	14	17	N/A	-6	N/A
9/30/2014	13	20	N/A	-8	N/A
6/30/2014	13	23	N/A	-9	N/A
3/31/2014	13	34	N/A	-10	N/A
12/31/2013	12	46	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 1010 über der Sparquote liegt (2.3%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 1010 schneller wachsen werden als der Markt Hong Kong

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 1010 in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 1010 schneller wachsen werden als der Markt von Hong Kong.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 1010 schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1010 in 3 Jahren voraussichtlich hoch sein wird

Sky Blue 11 Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

PacRay International Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2021

PacRay International Holdings Limited Provides Earnings Guidance for the Year Ended December 31, 2020

Recent updates

Less than half of directors are independent

Sky Blue 11 Company Limited Announces Changes to Its Board and Change in Composition of Board Committees

Sky Blue 11 Company Limited Appoints Mak Tin Sang as Independent Non-Executive Director, Member of Audit Committee, Nomination Committee and Remuneration Committee

New major risk - Financial position

Sky Blue 11 Company Limited to Report First Half, 2024 Results on Aug 30, 2024

Sky Blue 11 Company Limited Announces Termination of Lam Fuk Tak as Chief Executive Officer

Sky Blue 11 Company Limited's (HKG:1010) 32% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sky Blue 11 Company Limited Announces Board Retirements

Sky Blue 11 Company Limited Announces Executive Changes

Sky Blue 11 Company Limited, Annual General Meeting, Jun 06, 2024

Sky Blue 11 Company Limited has filed a Follow-on Equity Offering in the amount of HKD 146.617076 million.

New major risk - Negative shareholders equity

Full year 2023 earnings released: HK$0.13 loss per share (vs HK$0.006 loss in FY 2022)

Now 22% overvalued

Balk 1798 Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Balk 1798 Group Limited (HKG:1010) Soars 29% But It's A Story Of Risk Vs Reward

Now 22% overvalued

Now 44% overvalued

It's Down 26% But Balk 1798 Group Limited (HKG:1010) Could Be Riskier Than It Looks

Not Many Are Piling Into Balk 1798 Group Limited (HKG:1010) Stock Yet As It Plummets 26%

New minor risk - Shareholder dilution

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 39%

Does Balk 1798 Group (HKG:1010) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Investor sentiment improves as stock rises 31%

First half 2023 earnings released: HK$0.002 loss per share (vs HK$0.042 loss in 1H 2022)

Balk 1798 Group Limited to Report First Half, 2023 Results on Aug 30, 2023

Shareholders Should Be Pleased With Balk 1798 Group Limited's (HKG:1010) Price

Balk 1798 Group Limited, Annual General Meeting, Jun 06, 2023

High number of new and inexperienced directors

Balk 1798 Group (HKG:1010) Takes On Some Risk With Its Use Of Debt

High number of new and inexperienced directors

First half 2022 earnings released: HK$0.042 loss per share (vs HK$0.029 loss in 1H 2021)

PacRay International Holdings Limited Announces Executive Changes

First half 2022 earnings released: HK$0.042 loss per share (vs HK$0.029 loss in 1H 2021)

PacRay International Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

PacRay International Holdings Limited, Annual General Meeting, Jun 06, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.016 loss in FY 2020)

PacRay International Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2021

PacRay International Holdings Limited Appoints Wang Yi as the Executive Director, with Effect from March 8, 2022

PacRay International Holdings Limited Announces Resignation of Duan Hongtao as Executive Director and Chairman of the Board

Non-Executive Director & Company Secretary Danqing Zhou has left the company

Executive Director Yinsheng Xu has left the company

First half 2021 earnings released: HK$0.029 loss per share (vs HK$0.004 loss in 1H 2020)

Executive Director Lin Yang has left the company

Executive Director has left the company

Independent Non-Executive Director has left the company

Executive Director has left the company

Full year 2020 earnings released: HK$0.016 loss per share (vs HK$0.063 loss in FY 2019)

PacRay International Holdings Limited Provides Earnings Guidance for the Year Ended December 31, 2020

PacRay International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: HK$1.96

Zhongying Int’l Holding Group Limited completed the acquisition of 45.1% stake in PacRay International Holdings Limited (SEHK:1010) from Vision2000 Venture Ltd. and other shareholders for approximately HKD 230 million.

If You Had Bought PacRay International Holdings' (HKG:1010) Shares Three Years Ago You Would Be Down 34%

Zhongying Int’l Holding Group Limited made an offer to acquire 56.34% stake in PacRay International Holdings Limited (SEHK:1010) from Vision2000 Venture Ltd. and other shareholders for approximately HKD 280 million.

New 90-day high: HK$0.90

New 90-day low: HK$0.70

First half earnings released

PacRay International Holdings Limited (SEHK:1010) completed the acquisition of 20.2% stake in Meridian Aviation Holdings Limited from Duan Hong Tao and Wang Yi.

First half earnings released

Pacray International Holdings Limited Announces Resignation of Xu Beinan as Chief Executive Officer

PacRay International Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - HK$1.79

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken